Provided by Tiger Fintech (Singapore) Pte. Ltd.

iTeos Therapeutics

7.26
-0.0900-1.22%
Volume:234.10K
Turnover:1.70M
Market Cap:277.29M
PE:-2.19
High:7.37
Open:7.31
Low:7.18
Close:7.35
Loading ...

Company Profile

Company Name:
iTeos Therapeutics
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
173
Office Location:
321 Arsenal Street,Watertown,Massachusetts,United States
Zip Code:
02472
Fax:
- -
Introduction:
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Directors

Name
Position
David Hallal
Director and Chairman of the Board
Michel Detheux
Chief Executive Officer and Director
Aaron Davis
Director
Ann D. Rhoads
Director
Derek Paul Di Rocco
Director
Detlev Biniszkiewicz
Director
Matthew Roden
Director
Robert Iannone
Director
Tim Van Hauwermeiren
Director
Tony Ho
Director

Shareholders

Name
Position
Michel Detheux
Chief Executive Officer and Director
Matthew Call
Chief Operating Officer
Matthew Gall
Chief Financial Officer
Joanne Jenkins Lager
Chief Medical Officer
Yvonne McGrath
Vice President, Research and Development